- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06746688
El ensayo es el primero en humanos, de fase I, abierto y de aumento de dosis para evaluar la seguridad y tolerabilidad de ES2B-C001 combinado con montanida o sin montanida, en pacientes con receptor 2 del factor de crecimiento epidérmico humano (HER2) Expresando cáncer de mama metastásico
Un primer ensayo de fase I, abierto y de aumento de dosis en humanos para evaluar la seguridad, tolerabilidad e inmunogenicidad/actividad antitumoral preliminar de ES2B-C001 con o sin montanida en cáncer de mama metastásico que expresa HER2
The trial is a first-in-human, phase I, open-label, dose-escalating trial to assess the safety and tolerability of ES2B-C001 combined with or without [adjuvant], in patients with human epidermal growth factor receptor 2 (HER2) expressing metastatic breast cancer.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Graz, Austria
- Medical University of Graz
-
Linz, Austria, 4010
- Ordensklinikum Linz GmbH Barmherzige Schwestern
-
Vienna, Austria, 1090
- Medical University Of Vienna
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients aged ≥18 years at screening visit.
- Diagnosis of HER2-expressing locally advanced, unresectable, or metastatic BC, with HER2 IHC level 1+, 2+ (either FISH negative or positive), or IHC level 3+, after undergoing 2-3 lines of anticancer therapy.
- Life expectancy of at least 3 months.
- ECOG performance status 0-2.
- Patients have adequate bone marrow, kidney, liver, heart, and lung function without clinically significant laboratory parameters as judged by the investigator.
- 12-lead ECG without clinically significant abnormalities and no LBBB, QRS duration >140 ms, or evidence of prior infarction.
- Recovered from side effects, adverse reactions, or adverse events due to prior therapy and/or surgery; any residual toxicities and toxicities related to current anticancer treatment must be ≤ Grade 2, except for alopecia, neuropathy or lymphoedema.
- If female, non-pregnant, postmenopausal, or practicing reliable contraception.
- If male, sterilized or using reliable contraception.
Exclusion Criteria:
- Any planned intravenous chemotherapy regimens or check point inhibitors, or previous therapy with those agents during the past 1 month and the patients are neutropenic. Maintenance therapy with a stable dose of HER2-directed mAbs or treatment with antibody drug conjugates (ADCs) for metastatic BC is allowed at the discretion of the treating physician.
- Symptomatic CNS metastatic disease requiring treatment with high dose steroids (i.e., above 10 mg of prednisone or equivalent) within 14 days prior to first administration of ES2B-C001 (with or without adjuvant).
- Concurrent or recent (within 21 days or 5 half-lives) involvement in any other clinical trial with an investigational drug, device, or other experimental intervention.
- Concomitant severe or uncontrolled underlying medical and/or mental disease unrelated to the tumor, which in the opinion of the investigator is likely to compromise patient safety and affect the trial's outcome.
- Previous documented coronary artery disease or congestive heart failure (>NYHA II).
- Echocardiography with LVEF <50%.
- Uncontrolled hypertension.
- Active, known, or suspected autoimmune disease, except thyroid conditions sufficiently controlled on thyroid hormone therapy, and controlled insulin dependent diabetes.
- Necessity for long-term immunosuppression (≤ 4 mg dexamethasone may be used transiently).
- Systemic infection requiring intravenous antibiotics within 14 days before dosing.
- Chronic use of anti-viral agents, except for human immunodeficiency virus (HIV) or hepatitis B or C virus (HBV, HCV) treatments.
- History of severe hypersensitivity reactions to any of the trial drug components.
- Has received a live or live-attenuated vaccine within 30 days prior to the first dose of trial treatment. Note: Administration of inactivated or recombinant vaccines/killed vaccines are allowed.
- Birthmarks, tattoos, wounds, or skin conditions on deltoid region/buttocks that may obscure the assessment of injection site reactions.
- Female patients who are pregnant, or lactating.
- Any infection (including SARS-CoV-2), that in the opinion of the investigator would, upon inclusion in the trial, lead to potentially harming patients' safety or integrity.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Cohorte C1: 50 µg ES2B-C001 con [adyuvante]
|
Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations. Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations. |
|
Experimental: Cohorte C2: 150 µg ES2B-C001 con [adyuvante]
|
Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations. Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations. |
|
Experimental: Cohorte C3: 450µg ES2B-C001 con o sin [adyuvante]
|
Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations. Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To determine the safety, tolerability, maximum tolerated dose (MTD) for ES2B-C001 alone or in combination with [adjuvant].
Periodo de tiempo: From enrolment to the end of study at week 18
|
|
From enrolment to the end of study at week 18
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To investigate the immunogenicity of ES2B-C001 alone or in combination with [adjuvant].
Periodo de tiempo: From enrolment to the end of study at week 18
|
Immunogenicity as humoral immune response: Total anti-HER2 Immunoglobulin G (IgG) and IgG lambda titers in sera by enzyme-linked immunosorbent assay (ELISA). |
From enrolment to the end of study at week 18
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Periodo de tiempo: From enrolment to the end of study at week 18
|
Percentage of patients with measurable disease at baseline achieving Complete Remission (CR) or Partial Response (PR) according to RECIST 1.1 as assessed by the investigator during routine follow up. |
From enrolment to the end of study at week 18
|
|
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Periodo de tiempo: From enrolment to the end of study at week 18
|
Percentage of patients with Disease Control Rate (DCR) according to RECIST 1.1 as assessed by the investigator during routine follow up. |
From enrolment to the end of study at week 18
|
|
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Periodo de tiempo: From enrolment to the end of study at week 18
|
Progression free survival (PFS) in patients with Stable Disease (SD), or PR, at the time of first dosing of ES2B-C001 alone or in combination with [adjuvant] according to RECIST 1.1. |
From enrolment to the end of study at week 18
|
|
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Periodo de tiempo: From enrolment to the end of study at week 18
|
Overall survival (OS) |
From enrolment to the end of study at week 18
|
|
To investigate the immunogenicity of ES2B-C001 alone or in combination with [adjuvant].
Periodo de tiempo: From enrolment to the end of study at week 18
|
Optionally, other immunogenicity and biomarker readouts: characterization of anti-HER2 immunoglobulins in selected sera, including isotyping (e.g. IgM, IgG and IgG subclasses IgG1-4, IgD, IgE, IgA); analysis of HER2 epitope recognition profiles; cellular immune responses; in vitro cell stimulation assays; and measuring circulating tumor DNA. |
From enrolment to the end of study at week 18
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Thomas K. Jorgensen, ExpreS2ion Biotechnologies
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- ES2B-C001-S01
- 2024-516333-12-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Within the study de-identified patient data will be shared with
- the operational study team, sponsor, auditor and for reporting of safety events to the regulatory agencies and EC
- Data Monitoring Committees/ or other independent committees during the study
- At the end - data listings are part of the Appendices of the CSR which will be shared to regulatory agencies and EC
Tipo de información de apoyo para compartir IPD
- SAVIA
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .